WuXi XDC and LigaChem Strengthen Collaboration for Next-Gen ADC Therapies

• WuXi XDC has signed an expanded Memorandum of Understanding (MOU) with LigaChem Biosciences to accelerate the development of antibody-drug conjugates (ADCs).

• The agreement strengthens their collaboration, leveraging WuXi XDC’s integrated ADC discovery, development, and manufacturing capabilities to support LigaChem’s pipeline.

WuXi XDC Cayman Inc., a contract research, development, and manufacturing organisation (CRDMO) specialising in ADCs and bioconjugates, has signed an expanded Memorandum of Understanding (MOU) with LigaChem Biosciences. The agreement broadens their existing collaboration to further accelerate the development of next-generation ADC therapies targeting cancer and other serious diseases.

Under the expanded MOU, WuXi XDC’s fully integrated ADC discovery platform will enhance the speed and efficiency of LigaChem’s ADC development pipeline. The partnership enables LigaChem to seamlessly transition ADC candidates from discovery to development stages while leveraging WuXi XDC’s expertise and technology.

LigaChem will also utilise WuXi XDC’s contract manufacturing capabilities to support multiple ADC projects. This strategic expansion strengthens both companies’ mission to deliver innovative ADC therapies addressing unmet patient needs.

“We are excited to expand our partnership with WuXi XDC,” said Dr. Yong-Zu Kim, CEO and President of LigaChem. “WuXi XDC’s expertise and comprehensive service offerings are crucial to the success of our ADC programs.”

The collaboration between WuXi XDC and LigaChem began in 2021, with both companies making significant progress in ADC innovation. This latest agreement reaffirms their commitment to advancing ADC therapies and bringing targeted treatment options to patients worldwide.